AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy

AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy

Non-small cell lung cancer with EGFR mutations are known to develop resistance to EGFR tyrosine kinase inhibitors. Here, the authors show AURKB activation to be associated with resistance in EGFR mutant lung cancer cells, and that AURKB is a therapeutic target in resistant tumours that lack the p.T7...

Full description

Bibliographic Details
Main Authors: Jordi Bertran-Alamillo, Valérie Cattan, Marie Schoumacher, Jordi Codony-Servat, Ana Giménez-Capitán, Frédérique Cantero, Mike Burbridge, Sonia Rodríguez, Cristina Teixidó, Ruth Roman, Josep Castellví, Silvia García-Román, Carles Codony-Servat, Santiago Viteri, Andrés-Felipe Cardona, Niki Karachaliou, Rafael Rosell, Miguel-Angel Molina-Vila
Format: Article
Language:English
Published: Nature Portfolio 2019-04-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-019-09734-5

Internet

https://doi.org/10.1038/s41467-019-09734-5

Similar Items